Onyx
Nexavar fails in lung cancer trial
June 15, 2010Research and Development Bayer, NSCLC, Nexavar, Onyx
Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
